1XKK

EGFR kinase domain complexed with a quinazoline inhibitor- GW572016


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.209 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Wood, E.R.Truesdale, A.T.McDonald, O.B.Yuan, D.Hassell, A.Dickerson, S.H.Ellis, B.Pennisi, C.Horne, E.Lackey, K.Alligood, K.J.Rusnak, D.W.Gilmer, T.M.Shewchuk, L.

(2004) Cancer Res 64: 6652-6659

  • DOI: 10.1158/0008-5472.CAN-04-1168
  • Primary Citation of Related Structures:  
    1XKK

  • PubMed Abstract: 
  • GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2. We determined the crystal structure of EGFR bound to GW572016. The compound is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously ...

    GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2. We determined the crystal structure of EGFR bound to GW572016. The compound is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously. Surprisingly, we found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa). Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation. We evaluated the duration of the drug effect after washing away free compound and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain. The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells. The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.


    Organizational Affiliation

    Department of Computational, Analytical and Structural Sciences, GlaxoSmithKline, Inc., Research Triangle Park, North Carolina 27709, USA. ew39216@gsk.com



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Epidermal growth factor receptorA352Homo sapiensMutation(s): 0 
Gene Names: EGFRERBB1ERBBHER1
EC: 2.7.1.112 (PDB Primary Data), 2.7.10.1 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P00533 (Homo sapiens)
Explore P00533 
Go to UniProtKB:  P00533
PHAROS:  P00533
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
FMM
Query on FMM

Download Ideal Coordinates CCD File 
D [auth A]N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
C29 H26 Cl F N4 O4 S
BCFGMOOMADDAQU-UHFFFAOYSA-N
 Ligand Interaction
PO4
Query on PO4

Download Ideal Coordinates CCD File 
B [auth A], C [auth A]PHOSPHATE ION
O4 P
NBIIXXVUZAFLBC-UHFFFAOYSA-K
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
FMMIC50:  10   nM  BindingDB
FMMIC50:  9   nM  BindingDB
FMMIC50:  140   nM  BindingDB
FMMKd:  8.600000381469727   nM  BindingDB
FMMIC50:  12   nM  BindingDB
FMMIC50:  11   nM  BindingDB
FMMKd:  2800   nM  BindingDB
FMMKd:  2.200000047683716   nM  BindingDB
FMMIC50:  8   nM  BindingDB
FMMIC50:  2.9000000953674316   nM  BindingDB
FMMIC50:  19   nM  BindingDB
FMMKd:  1.2000000476837158   nM  BindingDB
FMMKd:  2.799999952316284   nM  BindingDB
FMMIC50:  17   nM  BindingDB
FMMIC50:  280   nM  BindingDB
FMMIC50:  52.20000076293945   nM  BindingDB
FMMIC50:  32   nM  BindingDB
FMMIC50:  225   nM  BindingDB
FMMKi :  3   nM  PDBBind
FMMIC50:  16   nM  BindingDB
FMMIC50:  8.899999618530273   nM  BindingDB
FMMIC50:  38   nM  BindingDB
FMMKd:  2.4000000953674316   nM  BindingDB
FMMIC50:  7.900000095367432   nM  BindingDB
FMMKd:  3.5   nM  BindingDB
FMMIC50:  3   nM  BindingDB
FMMKd:  860   nM  BindingDB
FMMIC50:  27   nM  BindingDB
FMMIC50:  433   nM  BindingDB
FMMIC50:  26   nM  BindingDB
FMMKd:  4.199999809265137   nM  BindingDB
FMMKd:  3.9000000953674316   nM  BindingDB
FMMIC50:  7.599999904632568   nM  BindingDB
FMMKi:  3   nM  Binding MOAD
FMMIC50:  5.5   nM  BindingDB
FMMKd:  5.5   nM  BindingDB
FMMIC50:  52   nM  BindingDB
FMMKd:  2.0999999046325684   nM  BindingDB
FMMKd:  0.9200000166893005   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.209 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 45.653α = 90
b = 67.144β = 90
c = 102.88γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
SCALEPACKdata scaling
CNSrefinement
HKL-2000data reduction
CNSphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2004-12-07
    Type: Initial release
  • Version 1.1: 2008-04-30
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance